The proprotein convertase furin is required for trophoblast syncytialization

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Zhou, Z ^a,b   Zhang, Q ^a,c   Lu, X ^a,b   Wang, R ^a,b   Wang, H ^a   Wang, Y L ^a   Zhu, C ^a   Lin, H Y ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Furin; Placenta; Placenta specific knockdown; Syncytialization; Syncytiotrophoblast

Indexed keywords

FURIN; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUSION; CELL STRUCTURE; CHORIOCARCINOMA; CONTROLLED STUDY; CYTOTROPHOBLAST; EMBRYO DEVELOPMENT; EXPLANT; FEMALE; FIRST TRIMESTER PREGNANCY; GENE TARGETING; GESTATIONAL AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RNA INTERFERENCE; SYNCYTIOTROPHOBLAST; EMBRYO; LENTIVIRINAE; NIDATION; TROPHOBLAST;

LENTIVIRUS;

EID: 84876891543     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.106     Document Type: Article

References (53)

1. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120
3. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-Initiating cell. Cancer Res 2007; 67: 11234-11243
4. Tonini GP, Pistoia V. Molecularly guided therapy of neuroblastoma: A review of different approaches. Curr Pharm Des 2006; 12: 2303-2317
5. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261
6. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233
7. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-4757
8. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115
9. Burger JA, Kipps TJ. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-1767
10. Matsushima H, Bogenmann E. Modulation of neuroblastoma cell differentiation by the extracellular matrix. Int J Cancer 1992; 51: 727-732
11. Pezzolo A, Parodi F, Marimpietri D, Raffaghello L, Cocco C, Pistorio A et al. Oct-4/ Tenascin C neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res 2011; 21: 1470-1486
12. Castriconi R, Dondero A, Cilli M, Ognio E, Pezzolo A, De Giovanni B et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007; 56: 1733-1742
13. Karlsson J, Ora I, Porn-Ares I, Pahlman S. Arsenic trioxide-Induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004; 10: 3179-3188
14. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-2319
15. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 2008; 3: E2637
16. Hussein D, Punjaruk W, Storer LC, Shaw L, Othman R, Peet A et al. Pediatric brain tumor cancer stem cells: Cell cycle dynamics, DNA repair, and etoposide extrusion. Neuro Oncol 2011; 13: 70-83
17. Khalil MA, Hrabeta J, Cipro S, Stiborova M, Vicha A, Eckschlager T. Neuroblastoma stem cells -mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma 2012; 59: 37-46
18. Coulon A, Flahaut M, Muhlethaler-Mottet A, Meier R, Liberman J, Balmas-Bourloud K et al. Functional sphere profiling reveals the complexity of neuroblastoma tumor-Initiating cell model. Neoplasia 2011; 13: 991-1004
19. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, Duval M et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012; 60: 1144-1155
20. Oh SY, Sohn YW, Park JW, Park HJ, Jeon HM, Kim TK et al. Selective cell death of oncogenic Akt-Transduced brain cancer cells by etoposide through reactive oxygen species mediated damage. Mol Cancer Ther 2007; 6: 2178-2187
21. Marengo B, De Ciucis C, Ricciarelli R, Passalacqua M, Nitti M, Zingg JM et al. PKCdelta sensitizes neuroblastoma cells to L-buthionine-sulfoximine and etoposide inducing reactive oxygen species overproduction and DNA damage. PLoS One 2011; 6: E14661
22. Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000; 28: 1349-1361
23. Basu A, Woolard MD, Johnson CL. Involvement of protein kinase C-delta in DNA damageinduced apoptosis. Cell Death Differ 2001; 8: 899-908
24. Jiang XH, Tu SP, Cui JT, Lin MC, Xia HH, Wong WM et al. Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis. Cancer Res 2004; 64: 5787-5794
25. Domenicotti C, Marengo B, Verzola D, Garibotto G, Traverso N, Patriarca S et al. Role of PKC-delta activity in glutathione-depleted neuroblastoma cells. Free Radic Biol Med 2003; 35: 504-516
26. Marengo B, De Ciucis C, Verzola D, Pistoia V, Raffaghello L, Patriarca S et al. Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-Induced cytotoxic effects in neuroblastoma. Free Radic Biol Med 2008; 44: 474-482
27. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 2009; 8: 1168-1175
28. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/ mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722
29. Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS et al. CD26 regulates p38 mitogen-Activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-Anaplastic large cell lymphoma Karpas 299. Cancer Res 2005; 65: 6950-6956
30. Amran D, Sancho P, Fernandez C, Esteban D, Ramos AM, de Blas E et al. Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathioneindependent reduction in intracellular drug accumulation. Biochim Biophys Acta 2005; 1743: 269-279
31. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26: 3203-3213
32. Saxe JP, Tomilin A, Scholer HR, Plath K, Huang J. Post-Translational regulation of Oct4 transcriptional activity. PLoS One 2009; 4: E4467
33. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003; 4: 361-370
34. Pages G, Berra E, Milanini J, Levy AP, Pouyssegur J. Stress-Activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000; 275: 26484-26491
35. McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem 2005; 280: 20995-21003
36. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 2007; 25: 376-383
37. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 2010; 1806: 18-28
38. Jang BC, Sanchez T, Schaefers HJ, Trifan OC, Liu CH, Creminon C et al. Serum withdrawal-Induced post-Transcriptional stabilization of cyclooxygenase-2 mRNA in MDAMB-231 mammary carcinoma cells requires the activity of the p38 stress-Activated protein kinase. J Biol Chem 2000; 275: 39507-39515
39. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB et al. p38 mitogen-Activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res 2010; 70: 832-841
40. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY. p38 mitogen-Activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 2007; 67: 4320-4327
41. Raffaghello L, Cocco C, Corrias MV, Airoldi I, Pistoia V. Chemokines in neuroectodermal tumour progression and metastasis. Semin Cancer Biol 2009; 19: 97-102
42. Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-Activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci USA 2011; 108: 302-307
43. Hwang D, Jang BC, Yu G, Boudreau M. Expression of mitogen-Inducible cyclooxygenase induced by lipopolysaccharide: Mediation through both mitogen-Activated protein kinase and NF -kappaB signaling pathways in macrophages. Biochem Pharmacol 1997; 54: 87-96
44. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-3340
45. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66: 9794-9797
46. Zimmerman T, Blanco FJ. Inhibitors targeting the LFA-1/ICAM-1 cell-Adhesion interaction: Design and mechanism of action. Curr Pharm Des 2008; 14: 2128-2139
47. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: An application in cancer therapeutics. Curr Drug Targets 2011; 12: 1082-1093
48. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279: 1453-1461
49. Lee MR, Dominguez C. MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005; 12: 2979-2994
50. Gross N, Meier R. Chemokines in neuroectodermal cancers: The crucial growth signal from the soil. Semin Cancer Biol 2009; 19: 103-110
51. Toma JG, McKenzie IA, Bagli D, Miller FD. Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells 2005; 23: 727-737
52. Bernhard EJ, RJ Muschel. Ras metastasis, and matrix metalloproteinase 9. Methods Enzymol 2001; 333: 96-104
53. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202